 |
市場調査レポート
商品コード
1145383
皮膚充填剤の世界市場：産業動向・予測（～2029年）Global Dermal Fillers Market - Industry Trends and Forecast to 2029 |
||||||
● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。 詳細はお問い合わせください。
価格
| 皮膚充填剤の世界市場：産業動向・予測（～2029年） |
|
出版日: 2022年10月01日
発行: Data Bridge Market Research
ページ情報: 英文 246 Pages
納期: お問合せ
|
- 全表示
- 概要
- 図表
- 目次
概要
世界の皮膚充填剤の市場規模は、2022年～2029年の予測期間に実質的なCAGRで10.9％の成長を記録すると予測されています。
市場の成長に寄与する主な要因として、製品認可の増加、高齢者人口の増加が挙げられます。
当レポートでは、世界の皮膚充填剤市場について調査し、促進要因、抑制要因、機会、課題、製品タイプ・材料タイプ・用途・薬剤タイプ・エンドユーザー・流通チャネル・地域別分析、企業情勢、企業プロファイル等に関する情報を提供しています。
目次
第1章 イントロダクション
第2章 市場セグメンテーション
第3章 エグゼクティブサマリー
第4章 重要考察
- ポーターのファイブフォース
- PESTEL分析
- 疫学処置：国別
第5章 世界の皮膚充填剤市場の規制
第6章 市場概要
- 促進要因
- 低侵襲手術の普及率の上昇
- 高齢者人口の増加
- 皮膚充填剤の技術的進歩
- 市場企業による戦略的イニシアチブ
- 抑制要因
- 美容処置の高コスト
- 製品リコールのエスカレート
- 高度な皮膚充填剤注射器に関するFDAガイドライン
- 機会
- 医療費支出の増加
- 美容研究への資金調達活動の増加
- 新しい皮膚充填剤の進歩
- 皮膚充填剤の補償と偶発的クレームの増加
- 課題
- 熟練した専門家の不足
- 代替手段の利用可能性
第7章 世界の皮膚充填剤市場：製品タイプ別
- 概要
- 生分解性皮膚充填剤
- 一時的な生分解性
- 半永久的な生分解性
- 非生分解性皮膚充填剤
第8章 世界の皮膚充填剤市場：材料タイプ別
- 概要
- 天然皮膚充填剤
- ヒアルロン酸
- 脂肪
- コラーゲン
- その他
- 合成皮膚充填剤
- ポリ-L-乳酸
- カルシウムヒドロキシアパタイト
- ポリメチルメタクリレートミクロスフェア（PMMA）
- ポリアルキルイミド
- その他
第9章 世界の皮膚充填剤市場：用途別
- 概要
- フェイスリフト
- 鼻形成術
- 再建手術
- フェイスライン補正
- リップエンハンスメント
- たるみ肌
- 頬のくぼみ
- 皮膚のスムージング
- 歯科
- 美的修復
- リッププラム
- 傷跡の治療
- あごの増強
- 脂肪萎縮症治療
- 耳たぶの若返り
- その他
第10章 世界の皮膚充填剤市場：薬剤タイプ別
- 概要
- ブランド
- JUVEDERM
- RESTYLANE
- RADIESSE
- SCULPTRA
- ELLANSE
- BELLAFILL
- AQUAMID
- その他
- GENERIC
第11章 世界の皮膚充填剤市場：エンドユーザー別
- 概要
- 皮膚科クリニック
- 病院
- 外来手術センター
- 学術調査機関
- その他
第12章 世界の皮膚充填剤市場：流通チャネル別
- 概要
- 直接入札
- 薬局
- 小売薬局
- オンライン薬局
- その他
第13章 世界の皮膚充填剤市場：地域別
- 概要
- 北米
- 米国
- カナダ
- メキシコ
- 欧州
- ドイツ
- イタリア
- フランス
- 英国
- スペイン
- ロシア
- オランダ
- スイス
- ベルギー
- トルコ
- その他の欧州
- アジア太平洋
- 日本
- オーストラリア
- 韓国
- 中国
- インド
- タイ
- シンガポール
- マレーシア
- インドネシア
- フィリピン
- その他のアジア太平洋
- 南米
- ブラジル
- アルゼンチン
- その他の南米
- 中東・アフリカ
- 南アフリカ
- サウジアラビア
- アラブ首長国連邦
- エジプト
- イスラエル
- その他の中東・アフリカ
第14章 世界の皮膚充填剤市場：企業情勢
- 企業シェア分析：世界
- 企業シェア分析：北米
- 企業シェア分析：欧州
- 企業シェア分析：アジア太平洋
第15章 SWOT分析
第16章 企業プロファイル
- ALLERGAN（A SUBSIDIARY OF ABBVIE INC.）
- GALDERMA LABORATORIES, L.P
- MERZ NORTH AMERICA, INC（A SUBSIDIARY OF MERZ PHARMA）
- SINCLAIR PHARMA（A SUBSIDIARY OF HUADONG MEDICINE）
- REVANCE THERAPEUTICS, INC.
- AMALIAN
- ANIKA THERAPEUTICS, INC.
- BIOPLUS CO., LTD.
- BIOXIS PHARMACEUTICALS
- CONTURA INTERNATIONAL LTD.
- CROMA-PHARMA GMBH
- DSM
- FILLMED
- GIVAUDAN
- HUMEDIX（A SUBSIDIARY OF HUONS GLOBAL）
- IBSA FARMACEUTICI ITALIA SRL（A SUBSIDIARY OF IBSA INSTITUT BIOCHIMIQUE SA）
- IPSEN PHARMA.
- MEDYTROX
- MESOESTETIC
- PROLLENIUM MEDICAL TECHNOLOGIES
- SHANGHAI REYOUNGEL MEDICAL TECHNOLOGY COMPANY LIMITED
- SOSUM GLOBAL
- SUNEVA MEDICAL
- TEOXANE SA
- ZHEJIANG JINGJIA MEDICAL TECHNOLOGY CO., LTD
- ZIMMER AESTHETICS
第17章 アンケート
第18章 関連レポート
図表
LIST OF FIGURES
- FIGURE 1 GLOBAL DERMAL FILLERS MARKET: SEGMENTATION 36
- FIGURE 2 GLOBAL DERMAL FILLERS MARKET: DATA TRIANGULATION 39
- FIGURE 3 GLOBAL DERMAL FILLERS MARKET: DROC ANALYSIS 40
- FIGURE 4 GLOBAL DERMAL FILLERS MARKET : GLOBAL VS REGIONAL MARKET ANALYSIS 41
- FIGURE 5 GLOBAL DERMAL FILLERS MARKET : COMPANY RESEARCH ANALYSIS 41
- FIGURE 6 GLOBAL DERMAL FILLERS MARKET: INTERVIEW DEMOGRAPHICS 43
- FIGURE 7 GLOBAL DERMAL FILLERS MARKET: DBMR MARKET POSITION GRID 44
- FIGURE 8 GLOBAL DERMAL FILLERS MARKET: MARKET END USER COVERAGE GRID 46
- FIGURE 9 GLOBAL DERMAL FILLERS MARKET: VENDOR SHARE ANALYSIS 47
- FIGURE 10 GLOBAL DERMAL FILLERS MARKET: SEGMENTATION 51
- FIGURE 11 NORTH AMERICA IS EXPECTED TO DOMINATE THE DERMAL FILLERS MARKET AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029 52
- FIGURE 12 RISING DEMAND FOR ANTI-AGING DRUGS, AND GROWING POPULARITY OF NON-SURGICAL OR MINIMALLY INVASIVE AESTHETICS PROCEDURES ARE EXPECTED TO DRIVE THE GLOBAL DERMAL FILLERS MARKET IN THE FORECAST PERIOD 2022 TO 2029 53
- FIGURE 13 BIODEGRADABLE DERMAL FILLER SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL DERMAL FILLERS MARKET IN 2022 & 2029 53
- FIGURE 14 ASIA-PACIFIC IS THE FASTEST GROWING MARKET DERMAL FILLERS MANUFACTURERS IN THE FORECAST PERIOD OF 2022 TO 2029 54
- FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF GLOBAL DERMAL FILLERS MARKET 66
- FIGURE 16 GLOBAL DERMAL FILLERS MARKET: BY PRODUCT TYPE, 2021 76
- FIGURE 17 GLOBAL DERMAL FILLERS MARKET: BY PRODUCT TYPE, 2022-2029 (USD MILLION) 77
- FIGURE 18 GLOBAL DERMAL FILLERS MARKET: BY PRODUCT TYPE, CAGR (2022-2029) 77
- FIGURE 19 GLOBAL DERMAL FILLERS MARKET: BY PRODUCT TYPE, LIFELINE CURVE 78
- FIGURE 20 GLOBAL DERMAL FILLERS MARKET: BY MATERIAL TYPE, 2021 82
- FIGURE 21 GLOBAL DERMAL FILLERS MARKET, BY MATERIAL TYPE, 2022-2029 (USD MILLION) 83
- FIGURE 22 GLOBAL DERMAL FILLERS MARKET: BY MATERIAL TYPE, CAGR (2022-2029) 83
- FIGURE 23 GLOBAL DERMAL FILLERS MARKET: BY MATERIAL TYPE, LIFELINE CURVE 84
- FIGURE 24 GLOBAL DERMAL FILLERS MARKET : BY APPLICATION, 2021 107
- FIGURE 25 GLOBAL DERMAL FILLERS MARKET : BY APPLICATION, 2022-2029 (USD MILLION) 108
- FIGURE 26 GLOBAL DERMAL FILLERS MARKET : BY APPLICATION, CAGR (2022-2029) 109
- FIGURE 27 GLOBAL DERMAL FILLERS MARKET: BY APPLICATION, LIFELINE CURVE 109
- FIGURE 28 GLOBAL DERMAL FILLERS MARKET: BY DRUG TYPE, 2021 140
- FIGURE 29 GLOBAL DERMAL FILLERS MARKET, BY DRUG TYPE, 2022-2029 (USD MILLION) 141
- FIGURE 30 GLOBAL DERMAL FILLERS MARKET: BY DRUG TYPE, CAGR (2022-2029) 141
- FIGURE 31 GLOBAL DERMAL FILLERS MARKET: BY DRUG TYPE, LIFELINE CURVE 142
- FIGURE 32 GLOBAL DERMAL FILLERS MARKET: BY END USER, 2021 149
- FIGURE 33 GLOBAL DERMAL FILLERS MARKET: BY END USER, 2022-2029 (USD MILLION) 150
- FIGURE 34 GLOBAL DERMAL FILLERS MARKET: BY END USER, CAGR (2022-2029) 150
- FIGURE 35 GLOBAL DERMAL FILLERS MARKET: BY END USER, LIFELINE CURVE 151
- FIGURE 36 GLOBAL DERMAL FILLERS MARKET: BY DISTRIBUTION CHANNEL, 2021 156
- FIGURE 37 GLOBAL DERMAL FILLERS MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION) 157
- FIGURE 38 GLOBAL DERMAL FILLERS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029) 157
- FIGURE 39 GLOBAL DERMAL FILLERS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE 158
- FIGURE 40 GLOBAL DERMAL FILLERS MARKET: SNAPSHOT (2021) 164
- FIGURE 41 GLOBAL DERMAL FILLERS MARKET: BY REGION (2021) 166
- FIGURE 42 GLOBAL DERMAL FILLERS MARKET: BY REGION (2022 & 2029) 166
- FIGURE 43 GLOBAL DERMAL FILLERS MARKET: BY REGION (2021 & 2029) 167
- FIGURE 44 GLOBAL DERMAL FILLERS MARKET: BY PRODUCT TYPE (2022-2029) 167
- FIGURE 45 NORTH AMERICA DERMAL FILLERS MARKET: SNAPSHOT (2021) 169
- FIGURE 46 NORTH AMERICA DERMAL FILLERS MARKET: BY COUNTRY (2021) 171
- FIGURE 47 NORTH AMERICA DERMAL FILLERS MARKET: BY COUNTRY (2022 & 2029) 171
- FIGURE 48 NORTH AMERICA DERMAL FILLERS MARKET: BY COUNTRY (2021 & 2029) 172
- FIGURE 49 NORTH AMERICA DERMAL FILLERS MARKET: BY PRODUCT TYPE (2022-2029) 172
- FIGURE 50 EUROPE DERMAL FILLERS MARKET: SNAPSHOT (2021) 175
- FIGURE 51 EUROPE DERMAL FILLERS MARKET: BY COUNTRY (2021) 177
- FIGURE 52 EUROPE DERMAL FILLERS MARKET: BY COUNTRY (2022 & 2029) 177
- FIGURE 53 EUROPE DERMAL FILLERS MARKET: BY COUNTRY (2021 & 2029) 178
- FIGURE 54 EUROPE DERMAL FILLERS MARKET: BY PRODUCT TYPE (2022-2029) 178
- FIGURE 55 ASIA-PACIFIC DERMAL FILLERS MARKET: SNAPSHOT (2021) 181
- FIGURE 56 ASIA-PACIFIC DERMAL FILLERS MARKET: BY COUNTRY (2021) 183
- FIGURE 57 ASIA-PACIFIC DERMAL FILLERS MARKET: BY COUNTRY (2022 & 2029) 183
- FIGURE 58 ASIA-PACIFIC DERMAL FILLERS MARKET: BY COUNTRY (2021 & 2029) 184
- FIGURE 59 ASIA-PACIFIC DERMAL FILLERS MARKET: BY PRODUCT TYPE (2022-2029) 184
- FIGURE 60 SOUTH AMERICA DERMAL FILLERS MARKET: SNAPSHOT (2021) 187
- FIGURE 61 SOUTH AMERICA DERMAL FILLERS MARKET: BY COUNTRY (2021) 189
- FIGURE 62 SOUTH AMERICA DERMAL FILLERS MARKET: BY COUNTRY (2022 & 2029) 189
- FIGURE 63 SOUTH AMERICA DERMAL FILLERS MARKET: BY COUNTRY (2021 & 2029) 190
- FIGURE 64 SOUTH AMERICA DERMAL FILLERS MARKET: BY PRODUCT TYPE (2022-2029) 190
- FIGURE 65 MIDDLE EAST AND AFRICA DERMAL FILLERS MARKET: SNAPSHOT (2021) 193
- FIGURE 66 MIDDLE EAST AND AFRICA DERMAL FILLERS MARKET: BY COUNTRY (2021) 195
- FIGURE 67 MIDDLE EAST AND AFRICA DERMAL FILLERS MARKET: BY COUNTRY (2022 & 2029) 195
- FIGURE 68 MIDDLE EAST AND AFRICA DERMAL FILLERS MARKET: BY COUNTRY (2021 & 2029) 196
- FIGURE 69 MIDDLE EAST AND AFRICA DERMAL FILLERS MARKET: BY PRODUCT TYPE (2022-2029) 196
- FIGURE 70 GLOBAL DERMA FILLERS MARKET: COMPANY SHARE 2021 (%) 198
- FIGURE 71 NORTH AMERICA DERMA FILLERS MARKET: COMPANY SHARE 2021 (%) 199
- FIGURE 72 EUROPE DERMA FILLERS MARKET: COMPANY SHARE 2021 (%) 200
- FIGURE 73 ASIA-PACIFIC DERMA FILLERS MARKET: COMPANY SHARE 2021 (%) 201
目次
The Global dermal fillers market is projected to register a substantial CAGR of 10.9% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2020, the base year of calculation is 2021, and the forecast period is 2022 to 2029.
Market Segmentation:
Global Dermal Fillers Market, By Product Type (Biodegradable Dermal Fillers and Non-Biodegradable Dermal fillers), Material Type (Natural Dermal Fillers and Synthetic Dermal filler), Drug Type ( Branded and Generic), Application (Face Lift, Rhinoplasty, Reconstructive Surgery, Facial Line Correction,Lip, Enhancement, Sagging Skin, Cheek Depression, Skin Smoothing, Dentistry, Aesthetic Restoration, Scar Treatment, Chin Augmentation, Lipoatrophy Treatment, Earlobe Rejuvenation and Others), End User (Dermatology Clinics, Ambulatory Surgical Centers, Hospitals, Academic Research Institutes and Others), Distribution Channel (Direct Tender, Drug Stores, Retail Pharmacy, Online Pharmacy and Others) Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East and Africa) Industry Trends and Forecast to 2029.
Some of the major factors contributing to the growth of the dermal fillers market are:
Increase in product approval
Increase in geriatric population
Market Players:
The key market players for the dermal fillers market are listed below:
Allergan (A Subsidiary of Abbvie, Inc.)
Prollenium Medical Technologies
Suneva Medical
Revance Therapeutics, Inc.
FillMed Laboratories
Anika Therapeutics, Inc,
Ipsen Pharma
BIOXIS Pharmaceuticals
Zimmer Aesthetic
Zhejiang Jingjia Medical Technology Co. Ltd.
Medytox
Contura International ltd.
Shanghai Reyoungel Medical Technology Company Limited
Humedix (A subsidiary of HUONS GLOBAL)
Galderma Laboratories, L.P.
Merz North America, Inc. (A Subsidiary of Merz Pharma)
Croma-Pharma GmbH
Sinclair Pharma (A Subsidiary of Huadong Medicine Co., Ltd.)
Teoxane
BioPlus Co., Ltd.
Amalian
Givaudan
Mesoestetic
Sosum Global
DSM
IBSA Nordic ApS
TABLE OF CONTENTS
1 INTRODUCTION 25
- 1.1 OBJECTIVES OF THE STUDY 25
- 1.2 MARKET DEFINITION 25
- 1.3 OVERVIEW OF GLOBAL DERMAL FILLERS MARKET 25
- 1.4 LIMITATION 28
- 1.5 MARKETS COVERED 28
2 MARKET SEGMENTATION 36
- 2.1 MARKETS COVERED 36
- 2.2 GEOGRAPHICAL SCOPE 37
- 2.3 YEARS CONSIDERED FOR THE STUDY 38
- 2.4 CURRENCY AND PRICING 38
- 2.5 DBMR TRIPOD DATA VALIDATION MODEL 39
- 2.6 MULTIVARIATE MODELLING 42
- 2.7 PRODUCTS LIFELINE CURVE 42
- 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 43
- 2.9 DBMR MARKET POSITION GRID 44
- 2.10 MARKET END USER COVERAGE GRID 46
- 2.11 VENDOR SHARE ANALYSIS 47
- 2.12 SECONDARY SOURCES 48
- 2.13 ASSUMPTIONS 48
3 EXECUTIVE SUMMARY 49
4 PREMIUM INSIGHTS 53
- 4.1 PORTER'S FIVE FORCES 55
- 4.2 PESTEL ANALYSIS 56
- 4.3 EPIDEMIOLOGY PROCEDURES PER COUNTRY 56
5 REGULATIONS OF GLOBAL DERMAL FILLERS MARKET 61
6 MARKET OVERVIEW 65
- 6.1 DRIVERS 67
- 6.1.1 RISING PREVALENCE OF MINIMALLY INVASIVE PROCEDURES 67
- 6.1.2 INCREASING GERIATRIC POPULATION 67
- 6.1.3 TECHNOLOGICAL ADVANCEMENTS IN DERMAL FILLERS 68
- 6.1.4 STRATEGIC INITIATIVES BY MARKET PLAYERS 68
- 6.2 RESTRAINTS 69
- 6.2.1 HIGH COST OF AESTHETIC PROCEDURES 69
- 6.2.2 ESCALATING PRODUCT RECALL 70
- 6.2.3 FDA GUIDELINES FOR ADVANCED DERMAL FILLER INJECTORS 70
- 6.3 OPPORTUNITIES 71
- 6.3.1 INCREASING HEALTHCARE EXPENDITURE 71
- 6.3.2 INCREASING FUNDING ACTIVITIES FOR AESTHETIC RESEARCH 71
- 6.3.3 ADVANCEMENT IN THE NEW DERMAL FILLERS 72
- 6.3.4 INCREASING COMPENSATION AND ACCIDENTAL CLAIMS FOR DERMAL FILLER 73
- 6.4 CHALLENGES 74
- 6.4.1 LACK OF SKILLED PROFESSIONALS 74
- 6.4.2 AVAILABILITY OF ALTERNATIVES 74
7 GLOBAL DERMAL FILLERS MARKET, BY PRODUCT TYPE 75
- 7.1 OVERVIEW 76
- 7.2 BIODEGRADABLE DERMAL FILLERS 79
- 7.2.1 TEMPORARY BIODEGRADABLE 79
- 7.2.2 SEMI-PERMANENT BIODEGRADABLE 80
- 7.3 NON-BIODEGRADABLE DERMAL FILLERS 80
8 GLOBAL DERMAL FILLERS MARKET, BY MATERIAL TYPE 81
- 8.1 OVERVIEW 82
- 8.2 NATURAL DERMAL FILLERS 85
- 8.2.1 HYALURONIC ACID 85
- 8.2.1.1 BY TYPE 86
- 8.2.1.1.1 MONOPHASIC FILLERS 86
- 8.2.1.2 BY TYPE 86
- 8.2.1.2.1 MONODENSIFIED 86
- 8.2.1.2.2 POLYDENSIFIED 86
- 8.2.1.2.3 BIPHASIC FILLERS 86
- 8.2.1.3 BY MATERIAL TYPE 87
- 8.2.1.3.1 SINGLE-PHASE 87
- 8.2.1.3.2 DUPLEX-PHASE 87
- 8.2.1.4 BY APPLICATION 88
- 8.2.1.4.1 FACE LIFT 88
- 8.2.1.4.2 RHINOPLASTY 88
- 8.2.1.4.3 RECONSTRUCTIVE SURGERY 88
- 8.2.1.4.4 FACIAL LINE CORRECTION 89
- 8.2.1.4.5 LIP ENHANCEMENT 89
- 8.2.1.4.6 SAGGING SKIN 89
- 8.2.1.4.7 CHEEK DEPRESSION 89
- 8.2.1.4.8 SKIN SMOOTHING 89
- 8.2.1.4.9 DENTISTRY 89
- 8.2.1.4.10 AESTHETIC RESTORATION 89
- 8.2.1.4.11 SCAR TREATMENT 89
- 8.2.1.4.12 CHIN AUGMENTATION 89
- 8.2.1.4.13 LIPOATROPHY TREATMENT 89
- 8.2.1.4.14 EARLOBE REJUVENATION 89
- 8.2.1.4.15 OTHERS 90
- 8.2.1.1 BY TYPE 86
- 8.2.2 FAT 90
- 8.2.2.1 BY APPLICATION 90
- 8.2.2.1.1 FACE LIFT 91
- 8.2.2.1.2 RHINOPLASTY 91
- 8.2.2.1.3 RECONSTRUCTIVE SURGERY 91
- 8.2.2.1.4 FACIAL LINE CORRECTION 91
- 8.2.2.1.5 LIP ENHANCEMENT 91
- 8.2.2.1.6 SAGGING SKIN 91
- 8.2.2.1.7 CHEEK DEPRESSION 91
- 8.2.2.1.8 SKIN SMOOTHING 91
- 8.2.2.1.9 DENTISTRY 91
- 8.2.2.1.10 AESTHETIC RESTORATION 91
- 8.2.2.1.11 SCAR TREATMENT 91
- 8.2.2.1.12 CHIN AUGMENTATION 92
- 8.2.2.1.13 LIPOATROPHY TREATMENT 92
- 8.2.2.1.14 EARLOBE REJUVENATION 92
- 8.2.2.1.15 OTHERS 92
- 8.2.2.1 BY APPLICATION 90
- 8.2.3 COLLAGEN 92
- 8.2.3.1 BY APPLICATION 93
- 8.2.3.1.1 FACE LIFT 93
- 8.2.3.1.2 RHINOPLASTY 93
- 8.2.3.1.3 RECONSTRUCTIVE SURGERY 93
- 8.2.3.1.4 FACIAL LINE CORRECTION 94
- 8.2.3.1.5 LIP ENHANCEMENT 94
- 8.2.3.1.6 SAGGING SKIN 94
- 8.2.3.1.7 CHEEK DEPRESSION 94
- 8.2.3.1.8 SKIN SMOOTHING 94
- 8.2.3.1.9 DENTISTRY 94
- 8.2.3.1.10 AESTHETIC RESTORATION 94
- 8.2.3.1.11 SCAR TREATMENT 94
- 8.2.3.1.12 CHIN AUGMENTATION 94
- 8.2.3.1.13 LIPOATROPHY TREATMENT 94
- 8.2.3.1.14 EARLOBE REJUVENATION 94
- 8.2.3.1.15 OTHERS 95
- 8.2.3.1 BY APPLICATION 93
- 8.2.4 OTHERS 95
- 8.2.1 HYALURONIC ACID 85
- 8.3 SYNTHETIC DERMAL FILLERS 95
- 8.3.1 POLY-L-LACTIC ACID 96
- 8.3.1.1 BY APPLICATION 96
- 8.3.1.1.1 FACE LIFT 96
- 8.3.1.1.2 RHINOPLASTY 96
- 8.3.1.1.3 RECONSTRUCTIVE SURGERY 97
- 8.3.1.1.4 FACIAL LINE CORRECTION 97
- 8.3.1.1.5 LIP ENHANCEMENT 97
- 8.3.1.1.6 SAGGING SKIN 97
- 8.3.1.1.7 CHEEK DEPRESSION 97
- 8.3.1.1.8 SKIN SMOOTHING 97
- 8.3.1.1.9 DENTISTRY 97
- 8.3.1.1.10 AESTHETIC RESTORATION 97
- 8.3.1.1.11 SCAR TREATMENT 97
- 8.3.1.1.12 CHIN AUGMENTATION 97
- 8.3.1.1.13 LIPOATROPHY TREATMENT 97
- 8.3.1.1.14 EARLOBE REJUVENATION 98
- 8.3.1.1.15 OTHERS 98
- 8.3.1.1 BY APPLICATION 96
- 8.3.2 CALCIUM HYDROXYLAPATITE 98
- 8.3.2.1 BY APPLICATION 98
- 8.3.2.1.1 FACE LIFT 99
- 8.3.2.1.2 RHINOPLASTY 99
- 8.3.2.1.3 RECONSTRUCTIVE SURGERY 99
- 8.3.2.1.4 FACIAL LINE CORRECTION 99
- 8.3.2.1.5 LIP ENHANCEMENT 99
- 8.3.2.1.6 SAGGING SKIN 99
- 8.3.2.1.7 CHEEK DEPRESSION 99
- 8.3.2.1.8 SKIN SMOOTHING 99
- 8.3.2.1.9 DENTISTRY 99
- 8.3.2.1.10 AESTHETIC RESTORATION 99
- 8.3.2.1.11 SCAR TREATMENT 100
- 8.3.2.1.12 CHIN AUGMENTATION 100
- 8.3.2.1.13 LIPOATROPHY TREATMENT 100
- 8.3.2.1.14 EARLOBE REJUVENATION 100
- 8.3.2.1.15 OTHERS 100
- 8.3.2.1 BY APPLICATION 98
- 8.3.3 POLYMETHYL-METHACRYLATE MICROSPHERES (PMMA) 100
- 8.3.3.1 BY APPLICATION 101
- 8.3.3.1.1 FACE LIFT 101
- 8.3.3.1.2 RHINOPLASTY 101
- 8.3.3.1.3 RECONSTRUCTIVE SURGERY 101
- 8.3.3.1.4 FACIAL LINE CORRECTION 102
- 8.3.3.1.5 LIP ENHANCEMENT 102
- 8.3.3.1.6 SAGGING SKIN 102
- 8.3.3.1.7 CHEEK DEPRESSION 102
- 8.3.3.1.8 SKIN SMOOTHING 102
- 8.3.3.1.9 DENTISTRY 102
- 8.3.3.1.10 AESTHETIC RESTORATION 102
- 8.3.3.1.11 SCAR TREATMENT 102
- 8.3.3.1.12 CHIN AUGMENTATION 102
- 8.3.3.1.13 LIPOATROPHY TREATMENT 102
- 8.3.3.1.14 EARLOBE REJUVENATION 102
- 8.3.3.1.15 OTHERS 103
- 8.3.3.1 BY APPLICATION 101
- 8.3.4 POLYALKYLIMIDE 103
- 8.3.4.1 BY APPLICATION 103
- 8.3.4.1.1 FACE LIFT 104
- 8.3.4.1.2 RHINOPLASTY 104
- 8.3.4.1.3 RECONSTRUCTIVE SURGERY 104
- 8.3.4.1.4 FACIAL LINE CORRECTION 104
- 8.3.4.1.5 LIP ENHANCEMENT 104
- 8.3.4.1.6 SAGGING SKIN 104
- 8.3.4.1.7 CHEEK DEPRESSION 104
- 8.3.4.1.8 SKIN SMOOTHING 104
- 8.3.4.1.9 DENTISTRY 104
- 8.3.4.1.10 AESTHETIC RESTORATION 104
- 8.3.4.1.11 SCAR TREATMENT 104
- 8.3.4.1.12 CHIN AUGMENTATION 105
- 8.3.4.1.13 LIPOATROPHY TREATMENT 105
- 8.3.4.1.14 EARLOBE REJUVENATION 105
- 8.3.4.1.15 OTHERS 105
- 8.3.4.1 BY APPLICATION 103
- 8.3.5 OTHERS 105
- 8.3.1 POLY-L-LACTIC ACID 96
9 GLOBAL DERMAL FILLERS MARKET, BY APPLICATION 106
- 9.1 OVERVIEW 107
- 9.2 FACE LIFT 111
- 9.2.1 DEEP PLANE/SMAS FACE 111
- 9.2.2 MINI FACE LIFT 111
- 9.2.3 MID-FACE LIFT 112
- 9.2.4 JAW LINE 112
- 9.2.5 CUTANEOUS LIFT 112
- 9.2.6 TEMPORAL OR BROW LIFT 112
- 9.2.7 LIQUID FACE LIFT 112
- 9.2.8 OTHERS 112
- 9.2.8.1 JUVEDERM 112
- 9.2.8.2 RESTYLANE 112
- 9.2.8.3 SCULPTRA 113
- 9.2.8.4 DYSPORT 113
- 9.2.8.5 OTHERS 113
- 9.3 RHINOPLASTY 113
- 9.3.1 JUVEDERM 114
- 9.3.1.1 JUVEDERM XC 114
- 9.3.1.2 JUVEDERM ULTRA XC 114
- 9.3.1.3 JUVEDERM VOLUMA 114
- 9.3.1.4 JUVEDERM VOLBELLA 114
- 9.3.1.5 JUVEDERM VOLLURE XC 114
- 9.3.2 RESTYLANE 114
- 9.3.2.1 RESTYLANE SILK 115
- 9.3.2.2 RESTYLANE LYFT 115
- 9.3.2.3 RESTYLANE REFYNE 115
- 9.3.2.4 RESTYLANE DEFYNE 115
- 9.3.2.5 RESTYLANE-L 115
- 9.3.3 OTHERS 115
- 9.3.1 JUVEDERM 114
- 9.4 RECONSTRUCTIVE SURGERY 116
- 9.4.1 JUVEDERM 116
- 9.4.2 RESTYLANE 116
- 9.4.3 OTHERS 116
- 9.5 FACIAL LINE CORRECTION 117
- 9.5.1 DYNAMIC WRINKLES 117
- 9.5.2 STATIC WRINKLES 117
- 9.5.3 WRINKLE FOLDS 117
- 9.5.3.1 FOREHEAD LINES 118
- 9.5.3.2 WORRY LINES 118
- 9.5.3.3 BUNNIES 118
- 9.5.3.4 CROW'S FEET 118
- 9.5.3.5 LAUGH LINES 118
- 9.5.3.6 LIP LINES 118
- 9.5.3.7 MARIONETTE LINES 118
- 9.5.3.8 OTHERS 119
- 9.5.3.8.1 JUVEDERM 119
- 9.5.3.8.2 RESTYLANE 119
- 9.5.3.8.3 RADIESSE 119
- 9.5.3.8.4 BELOTERO 119
- 9.5.3.8.5 OTHERS 119
- 9.6 LIP ENHANCEMENT 120
- 9.6.1 JUVEDERM 121
- 9.6.1.1 JUVEDERM XC 121
- 9.6.1.2 JUVEDERM ULTRA XC 121
- 9.6.1.3 JUVEDERM VOLUMA 121
- 9.6.1.4 JUVEDERM VOLBELLA 121
- 9.6.1.5 JUVEDERM VOLLURE XC 121
- 9.6.2 RESTYLANE 122
- 9.6.2.1 RESTYLANE SILK 122
- 9.6.2.2 RESTYLANE LYFT 122
- 9.6.2.3 RESTYLANE REFYNE 122
- 9.6.2.4 RESTYLANE DEFYNE 122
- 9.6.2.5 RESTYLANE-L 122
- 9.6.3 BELOTERO BALANCE 122
- 9.6.4 REVANESSE VERSA 122
- 9.6.5 HYLAFORM 123
- 9.6.6 PREVELLE SILK 123
- 9.6.7 OTHERS 123
- 9.6.1 JUVEDERM 121
- 9.7 SAGGING SKIN 123
- 9.7.1 JUVEDERM 124
- 9.7.2 RESTYLANE 124
- 9.7.3 BELOTERO 124
- 9.7.4 OTHERS 124
- 9.8 CHEEK DEPRESSION 124
- 9.8.1 JUVEDERM VOLUMA 125
- 9.8.2 RESTYLANE-LYFT 125
- 9.8.3 SCULPTRA 125
- 9.8.4 RADIESSE 125
- 9.8.5 OTHERS 125
- 9.9 SKIN SMOOTHENING 126
- 9.9.1 RESTYLANE 126
- 9.9.2 BELOTERO 126
- 9.9.3 BELLAFIL 126
- 9.9.4 OTHERS 127
- 9.10 DENTISTRY 127
- 9.10.1 JUVEDERM 127
- 9.10.2 RESTYLANE 127
- 9.10.3 RADIESSE 127
- 9.10.4 OTHERS 128
- 9.11 AESTHETIC RESTORATION 128
- 9.11.1 JUVEDERM 129
- 9.11.1.1 JUVEDERM ULTRA XC 129
- 9.11.1.2 JUVEDERM VOLLURE XC 129
- 9.11.1.3 JUVEDERM VOLBELLA XC 129
- 9.11.2 RESTYLANE 129
- 9.11.2.1 RESTYLANE-L 130
- 9.11.2.2 RESTYLANE SILK 130
- 9.11.2.3 RESTYLANE REFYNE AND DEFYNE 130
- 9.11.2.4 RESTYLANE LYFT 130
- 9.11.1 JUVEDERM 129
- 9.12 REVANESSE VERSA 130
- 9.13 SCULPTRA 130
- 9.14 RHA 130
- 9.14.1 RHA 2 131
- 9.14.2 RHA 3 131
- 9.14.3 RHA 4 131
- 9.15 BELLAFIL 131
- 9.16 BELOTERO BALANCE 131
- 9.17 OTHERS 131
- 9.18 LIP PLUM 131
- 9.18.1 RESTYLANE 132
- 9.18.2 BELOTERO 132
- 9.18.3 OTHERS 132
- 9.19 SCAR TREATMENT 132
- 9.19.1 JUVEDERM 133
- 9.19.2 RESTYLANE 133
- 9.19.3 RADIESSE 133
- 9.19.4 BELOTERO 133
- 9.19.5 PERLANE 133
- 9.19.6 OTHERS 134
- 9.19.6.1 KELOID SCARS 134
- 9.19.6.2 CONTRACTURE SCARS 134
- 9.19.6.3 HYPERTROPHIC SCARS 134
- 9.19.6.4 ACNE SCARS 134
- 9.19.6.5 OTHERS 134
- 9.20 CHIN AUGMENTATION 135
- 9.20.1 JUVEDERM VOLUMA XC 135
- 9.20.2 RESTYLANE 135
- 9.20.3 OTHERS 135
- 9.21 LIPOATROPHY TREATMENT 136
- 9.21.1 SCULPTRA 136
- 9.21.2 OTHERS 136
- 9.22 EARLOBE REJUVENATION 137
- 9.22.1 JUVEDERM 137
- 9.22.2 RESTYLANE 137
- 9.22.3 SCULPTRA 138
- 9.22.4 BELOTERO 138
- 9.22.5 ELLANSE 138
- 9.22.6 OTHERS 138
- 9.23 OTHERS 138
10 GLOBAL DERMAL FILLERS MARKET, BY DRUG TYPE 139
- 10.1 OVERVIEW 140
- 10.2 BRANDED 143
- 10.2.1 JUVEDERM 144
- 10.2.1.1 JUVEDERM XC 144
- 10.2.1.2 JUVEDERM ULTRA XC 144
- 10.2.1.3 JUVEDERM ULTRA PLUS XC 144
- 10.2.1.4 JUVEDERM VOLBELLA 144
- 10.2.1.5 JUVEDERM VOLUMA 144
- 10.2.1.6 JUVEDERM VOLLURE 144
- 10.2.2 RESTYLANE 145
- 10.2.2.1 RESTYLANE-L 145
- 10.2.2.2 RESTYLANE REFYNE 145
- 10.2.2.3 RESTYLANE DEFYNE 145
- 10.2.2.4 RESTYLANE LYFT 145
- 10.2.2.5 RESTYLANE SILK 145
- 10.2.2.6 RESTYLANE KYSSE 145
- 10.2.2.7 RESTYLANE CONTOUR 146
- 10.2.3 RADIESSE 146
- 10.2.4 SCULPTRA 146
- 10.2.5 ELLANSE 146
- 10.2.5.1 ELLANSE-S 146
- 10.2.5.2 ELLANSE-M 146
- 10.2.5.3 ELLANSE-L 146
- 10.2.5.4 ELLANSE-E 146
- 10.2.6 BELLAFILL 147
- 10.2.7 AQUAMID 147
- 10.2.8 OTHERS 147
- 10.2.1 JUVEDERM 144
- 10.3 GENERIC 147
11 GLOBAL DERMAL FILLERS MARKET, BY END USER 148
- 11.1 OVERVIEW 149
- 11.2 DERMATOLOGY CLINICS 152
- 11.3 HOSPITALS 152
- 11.4 AMBULATORY SURGICAL CENTERS 153
- 11.5 ACADEMIC RESEARCH INSTITUTES 153
- 11.6 OTHERS 154
12 GLOBAL DERMAL FILLERS MARKET, BY DISTRIBUTION CHANNEL 155
- 12.1 OVERVIEW 156
- 12.2 DIRECT TENDER 159
- 12.3 DRUG STORES 159
- 12.4 RETAIL PHARMACY 160
- 12.5 ONLINE PHARMACY 160
- 12.6 OTHERS 161
13 GLOBAL DERMAL FILLERS MARKET, BY GEOGRAPHY 162
- 13.1 OVERVIEW 163
- 13.2 NORTH AMERICA 168
- 13.2.1 U.S. 173
- 13.2.2 CANADA 173
- 13.2.3 MEXICO 173
- 13.3 EUROPE 174
- 13.3.1 GERMANY 179
- 13.3.2 ITALY 179
- 13.3.3 FRANCE 179
- 13.3.4 U.K. 179
- 13.3.5 SPAIN 179
- 13.3.6 RUSSIA 179
- 13.3.7 NETHERLANDS 179
- 13.3.8 SWITZERLAND 179
- 13.3.9 BELGIUM 179
- 13.3.10 TURKEY 179
- 13.3.11 REST OF EUROPE 179
- 13.4 ASIA-PACIFIC 180
- 13.4.1 JAPAN 185
- 13.4.2 AUSTRALIA 185
- 13.4.3 SOUTH KOREA 185
- 13.4.4 CHINA 185
- 13.4.5 INDIA 185
- 13.4.6 THAILAND 185
- 13.4.7 SINGAPORE 185
- 13.4.8 MALAYSIA 185
- 13.4.9 INDONESIA 185
- 13.4.10 PHILIPPINES 185
- 13.4.11 REST OF ASIA-PACIFIC 185
- 13.5 SOUTH AMERICA 186
- 13.5.1 BRAZIL 191
- 13.5.2 ARGENTINA 191
- 13.5.3 REST OF SOUTH AMERICA 191
- 13.6 MIDDLE EAST AND AFRICA 192
- 13.6.1 SOUTH AFRICA 197
- 13.6.2 SAUDI ARABIA 197
- 13.6.3 U.A.E 197
- 13.6.4 EGYPT 197
- 13.6.5 ISRAEL 197
- 13.6.6 REST OF MIDDLE EAST AND AFRICA 197
14 GLOBAL DERMA FILLERS MARKET: COMPANY LANDSCAPE 198
- 14.1 COMPANY SHARE ANALYSIS: GLOBAL 198
- 14.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 199
- 14.3 COMPANY SHARE ANALYSIS: EUROPE 200
- 14.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 201
15 SWOT ANALYSIS 202
16 COMPANY PROFILE 203
- 16.1 ALLERGAN (A SUBSIDIARY OF ABBVIE INC.) 203
- 16.1.1 COMPANY SNAPSHOT 203
- 16.1.2 REVENUE ANALYSIS 203
- 16.1.3 COMPANY SHARE ANALYSIS 204
- 16.1.4 PRODUCT PORTFOLIO 204
- 16.1.5 RECENT DEVELOPMENTS 204
- 16.2 GALDERMA LABORATORIES, L.P 206
- 16.2.1 COMPANY SNAPSHOT 206
- 16.2.2 COMPANY SHARE ANALYSIS 206
- 16.2.3 PRODUCT PORTFOLIO 207
- 16.2.4 RECENT DEVELOPMENTS 207
- 16.3 MERZ NORTH AMERICA, INC (A SUBSIDIARY OF MERZ PHARMA) 208
- 16.3.1 COMPANY SNAPSHOT 208
- 16.3.2 COMPANY SHARE ANALYSIS 208
- 16.3.3 PRODUCT PORTFOLIO 209
- 16.3.4 RECENT DEVELOPMENTS 209
- 16.4 SINCLAIR PHARMA (A SUBSIDIARY OF HUADONG MEDICINE) 211
- 16.4.1 COMPANY SNAPSHOT 211
- 16.4.2 COMPANY SHARE ANALYSIS 211
- 16.4.3 PRODUCT PORTFOLIO 212
- 16.4.4 RECENT DEVELOPMENT 212
- 16.5 REVANCE THERAPEUTICS, INC. 213
- 16.5.1 COMPANY SNAPSHOT 213
- 16.5.2 REVENUE ANALYSIS 213
- 16.5.3 COMPANY SHARE ANALYSIS 214
- 16.5.4 PRODUCT PORTFOLIO 214
- 16.5.5 RECENT DEVELOPMENTS 214
- 16.6 AMALIAN 215
- 16.6.1 COMPANY SNAPSHOT 215
- 16.6.2 PRODUCT PORTFOLIO 215
- 16.6.3 RECENT DEVELOPMENTS 215
- 16.7 ANIKA THERAPEUTICS, INC. 216
- 16.7.1 COMPANY SNAPSHOT 216
- 16.7.2 REVENUE ANALYSIS 216
- 16.7.3 PRODUCT PORTFOLIO 217
- 16.7.4 RECENT DEVELOPMENTS 217
- 16.8 BIOPLUS CO., LTD. 218
- 16.8.1 COMPANY SNAPSHOT 218
- 16.8.2 PRODUCT PORTFOLIO 218
- 16.8.3 RECENT DEVELOPMENTS 219
- 16.9 BIOXIS PHARMACEUTICALS 220
- 16.9.1 COMPANY SNAPSHOT 220
- 16.9.2 PRODUCT PORTFOLIO 220
- 16.9.3 RECENT DEVELOPMENTS 220
- 16.10 CONTURA INTERNATIONAL LTD. 221
- 16.10.1 COMPANY SNAPSHOT 221
- 16.10.2 PRODUCT PORTFOLIO 221
- 16.10.3 RECENT DEVELOPMENTS 221
- 16.11 CROMA-PHARMA GMBH 222
- 16.11.1 COMPANY SNAPSHOT 222
- 16.11.2 PRODUCT PORTFOLIO 222
- 16.11.3 RECENT DEVELOPMENT 222
- 16.12 DSM 223
- 16.12.1 COMPANY SNAPSHOT 223
- 16.12.2 PRODUCT PORTFOLIO 223
- 16.12.3 RECENT DEVELOPMENT 223
- 16.13 FILLMED 224
- 16.13.1 COMPANY SNAPSHOT 224
- 16.13.2 PRODUCT PORTFOLIO 224
- 16.13.3 RECENT DEVELOPMENT 224
- 16.14 GIVAUDAN 225
- 16.14.1 COMPANY SNAPSHOT 225
- 16.14.2 RECENT FINANCIALS 225
- 16.14.3 PRODUCT PORTFOLIO 226
- 16.14.4 RECENT DEVELOPMENT 226
- 16.15 HUMEDIX (A SUBSIDIARY OF HUONS GLOBAL) 227
- 16.15.1 COMPANY SNAPSHOT 227
- 16.15.2 REVENUE ANALYSIS 227
- 16.15.3 PRODUCT PORTFOLIO 228
- 16.15.4 RECENT DEVELOPMENTS 228
- 16.16 IBSA FARMACEUTICI ITALIA SRL (A SUBSIDIARY OF IBSA INSTITUT BIOCHIMIQUE SA) 229
- 16.16.1 COMPANY SNAPSHOT 229
- 16.16.2 PRODUCT PORTFOLIO 229
- 16.16.3 RECENT DEVELOPMENT 229
- 16.17 IPSEN PHARMA. 230
- 16.17.1 COMPANY SNAPSHOT 230
- 16.17.2 REVENUE ANALYSIS 230
- 16.17.3 PRODUCT PORTFOLIO 231
- 16.17.4 RECENT DEVELOPMENT 231
- 16.18 MEDYTROX 232
- 16.18.1 COMPANY SNAPSHOT 232
- 16.18.2 PRODUCT PORTFOLIO 232
- 16.18.3 RECENT DEVELOPMENTS 232
- 16.19 MESOESTETIC 233
- 16.19.1 COMPANY SNAPSHOT 233
- 16.19.2 PRODUCT PORTFOLIO 233
- 16.19.3 RECENT DEVELOPMENTS 233
- 16.20 PROLLENIUM MEDICAL TECHNOLOGIES 234
- 16.20.1 COMPANY SNAPSHOT 234
- 16.20.2 PRODUCT PORTFOLIO 234
- 16.20.3 RECENT DEVELOPMENT 234
- 16.21 SHANGHAI REYOUNGEL MEDICAL TECHNOLOGY COMPANY LIMITED 235
- 16.21.1 COMPANY SNAPSHOT 235
- 16.21.2 PRODUCT PORTFOLIO 235
- 16.21.3 RECENT DEVELOPMENTS 235
- 16.22 SOSUM GLOBAL 236
- 16.22.1 COMPANY SNAPSHOT 236
- 16.22.2 PRODUCT PORTFOLIO 236
- 16.22.3 RECENT DEVELOPMENT 236
- 16.23 SUNEVA MEDICAL 237
- 16.23.1 COMPANY SNAPSHOT 237
- 16.23.2 PRODUCT PORTFOLIO 237
- 16.23.3 RECENT DEVELOPMENT 237
- 16.24 TEOXANE SA 238
- 16.24.1 COMPANY SNAPSHOT 238
- 16.24.2 PRODUCT PORTFOLIO 238
- 16.24.3 RECENT DEVELOPMENTS 238
- 16.25 ZHEJIANG JINGJIA MEDICAL TECHNOLOGY CO., LTD 240
- 16.25.1 COMPANY SNAPSHOT 240
- 16.25.2 PRODUCT PORTFOLIO 240
- 16.25.3 RECENT DEVELOPMENT 240
- 16.26 ZIMMER AESTHETICS 241
- 16.26.1 COMPANY SNAPSHOT 241
- 16.26.2 PRODUCT PORTFOLIO 241
- 16.26.3 RECENT DEVELOPMENTS 241
